multiple sclerosis

arrow miss target fail attempt try
Biotech

Immunic MS asset misses primary goal of midstage trial

IMU-838 showed only “modest benefit” over placebo at improving the yearly rate of percent brain volume change in patients with progressive MS.
Darren Incorvaia Apr 30, 2025 3:05pm
MA strategy deal block push come together form

Acelyrin to be absorbed into Alumis in all-stock merger

Feb 7, 2025 5:35am
Image comparing healthy and degraded myelin sheath

Investigational MS drug restores mobility in mice

Jan 2, 2025 2:15pm
lightbulb explosion art

Sanofi will deploy new AI tool in late-stage MS trials

Nov 13, 2024 7:40am
failure crash no fail rocket cancelled end

Sanofi flunks MS study, dealing another blow to Denali pact

Oct 11, 2024 5:56am
positive negative up down good bad mixed

Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies

Sep 20, 2024 7:07am